Eczema Beyond Steroids: What the Rungs Above Hydrocortisone Actually Do

Where the steroid ladder legitimately stops

Topical corticosteroids are not the villain of this story. They are cheap, fast, extensively studied, and for the majority of flares they are exactly the right tool. The problem is that they are also where treatment tends to come to rest — a mid-potency tube renewed year after year, used reactively, on a disease that is chronic by definition.

The ladder has two genuine ceilings, and neither is the one people worry about. The first is anatomical. Steroid potency is stratified into classes, and the sites where eczema is most socially punishing — eyelids, face, neck, the flexures, the groin — are the sites where the skin is thinnest, occlusion is highest, and absorption is greatest. That is where atrophy, telangiectasia and perioral dermatitis actually come from, and it is why potency alone can never be scaled up to solve a stubborn eyelid. The second ceiling is duration. A drug used intermittently on a relapsing condition can only ever chase flares that have already started.

There is a third problem that runs in the opposite direction and gets far less attention: chronic underuse. Fear of steroids is widespread enough to have its own literature, and it produces a familiar pattern — a tube prescribed, applied thinly for three days, abandoned at the first sign of improvement, then blamed for not working. Dose is measurable. The fingertip unit — the ribbon of product from an adult index fingertip to the first crease, roughly half a gram, enough for about two palms of skin — is the standard clinical yardstick, and our FTU Calculator turns a body area into an actual quantity. Before deciding a steroid failed, it is worth establishing that a steroid was applied.

The boxed warning that the data did not support

Topical calcineurin inhibitors — tacrolimus ointment and pimecrolimus cream — occupy an odd position in eczema care: mechanistically ideal for the sites steroids can't safely hold, and saddled with a warning that scared a generation of prescribers away from them. In 2006 the FDA applied a boxed warning about a theoretical malignancy risk, reasoning from systemic calcineurin inhibition in transplant patients and from high-dose animal studies rather than from human topical data.

The human topical data eventually arrived. A prospective pediatric cohort followed 7,954 children who had used topical tacrolimus for at least six weeks, across 314 sites in nine countries, for ten years. Over 44,629 person-years there were six confirmed incident cancers — a standardized incidence ratio of 1.01 against matched national registry data, with a confidence interval of 0.37 to 2.20. No lymphomas occurred at all. That is about as close to a null result as observational oncology gets.

What calcineurin inhibitors do offer is the one thing steroids structurally cannot: no collagen suppression, so no atrophy, which makes them usable indefinitely on eyelids, faces and folds. The real cost is tolerability rather than safety — a burning or stinging sensation on application that is worst in the first days and on the most inflamed skin, which is precisely when patients are least inclined to persevere. Settling the skin with a short steroid course first, then switching, is the practical workaround, and it is worth knowing about before you abandon the tube on day two.

Two very different answers to the word 'nonsteroidal'

The topical middle ground has filled in fast, and the two newer classes are not interchangeable. PDE4 inhibitors raise intracellular cyclic AMP and damp down inflammatory cytokine production; topical JAK inhibitors block signal transduction downstream of a wide set of cytokine receptors, including the itch pathways.

The numbers tell the story of how much that mechanistic difference is worth. Crisaborole, the first PDE4 ointment approved for eczema, achieved its 28-day endpoint of clear-or-almost-clear plus a two-grade improvement in 32.8% of patients versus 25.4% on vehicle in one pivotal trial, and 31.4% versus 18.0% in the other. Statistically significant; a modest margin in the first study by any reading. Roflumilast cream 0.15%, a later and more potent PDE4 inhibitor dosed once daily, hit the same style of endpoint at four weeks in 32.0% versus 15.2% and 28.9% versus 12.0%, with EASI-75 rates of 43.2% versus 22.0%. Ruxolitinib cream 1.5% reached treatment success at eight weeks in 53.8% and 51.3% of patients versus 15.1% and 7.6% on vehicle — and produced statistically significant itch reduction within twelve hours of the first application, which is a genuinely different experience from waiting a fortnight to feel better.

The caveats are real and worth stating plainly. These are separate trials with different populations, different durations and different baseline severities; lining the percentages up in a row is convenient, not valid. The topical JAK trials enrolled patients with 3% to 20% affected body surface area, and that ceiling is part of the label — this is not a class for someone whose eczema covers half of them. Topical ruxolitinib also carries the class boxed warning inherited from oral JAK inhibitors, despite minimal systemic exposure at label-compliant use. And cost is the quiet gatekeeper: all three classes cost multiples of a generic steroid, and prior authorization is where a lot of good plans die.

Biologics, and what 'inadequately controlled' really means

The bar for systemic therapy is lower than most people assume. The pivotal dupilumab trials enrolled adults with moderate-to-severe disease whose eczema was inadequately controlled by topical treatment — not people who had exhausted every option, not people hospitalized for it. If your disease is moderate, your topicals are being used properly, and it is still running your life, you meet the description that the evidence base was built on.

What those trials found is worth holding in both hands at once. Across the two identically designed studies, 38% and 36% of dupilumab-treated patients reached clear or almost clear with a two-grade improvement at sixteen weeks, against 10% and 8% on placebo. That is a large treatment effect and a real change in what is achievable for people whose eczema had no ceiling before. It is also, read honestly, roughly six in ten who did not reach that endpoint. Biologics moved the distribution; they did not abolish the disease. Conjunctivitis and injection-site reactions were more common on drug than placebo, and conjunctivitis in particular has remained a recognizable feature of this class in practice.

Since then the systemic shelf has widened considerably — additional IL-13-directed antibodies and oral JAK inhibitors with faster onset and a heavier monitoring burden — and ↗the eczema pathway tracks that escalation in the order clinicians actually work through it. The point worth taking from the trial data is structural: 'failed topicals' is a conversation to have at a scheduled review, not a threshold you are supposed to prove through years of endurance.

The strategy almost nobody gets prescribed

The single most underused idea in eczema care is not a drug at all. It is when you apply the one you already have.

A multicentre randomised trial stabilised patients with moderate-to-severe atopic dermatitis on regular fluticasone, then split them: everyone continued daily emollient, but one group also applied the steroid twice weekly to the areas that usually flared — including skin that currently looked normal. Median time to relapse was six weeks on emollient alone and beyond sixteen weeks with the twice-weekly steroid added. Patients on the cream formulation were 5.8 times less likely to relapse (95% CI 3.1 to 10.8). Adverse events did not differ between groups.

That is proactive, or maintenance, dosing, and the mental shift it requires is treating a site rather than a flare. Subclinical inflammation persists in skin that has visibly cleared; twice-weekly application keeps it suppressed instead of waiting for it to break through. The same logic now underpins maintenance regimens with calcineurin inhibitors and with the newer nonsteroidals.

Every rung of this ladder sits on top of an emollient layer that does not change. A ceramide-dominant cream like ↗CeraVe Moisturizing Cream or the ↗La Roche-Posay Toleriane Double Repair on the face works because ↗ceramides, cholesterol and free fatty acids are the actual mortar of the stratum corneum, and eczematous skin is measurably short of them. For fissured hands and feet, a petrolatum-led ointment such as ↗CeraVe Healing Ointment does the occlusive job that no lotion will; on infants, something deliberately plain like ↗CeraVe Baby Moisturizing Cream avoids the sensitizers that complicate the picture later. ↗Our eczema moisturizer ranking and ↗the eczema routine cover how to layer that base without smothering the active.

What we think you should do with this

If your eczema is controlled on a steroid used properly and intermittently, nothing here is an argument to change. That is a good outcome and the cheapest one available.

If it isn't, the useful question is not 'what's stronger?' but 'what problem is my current treatment failing at?' Thin skin at a chronic site points to a calcineurin inhibitor. Widespread mild-to-moderate disease that you cannot keep steroids on indefinitely points to a PDE4 inhibitor. Itch that dominates everything else points toward the JAK class. Disease that keeps returning across your whole body regardless of what you put on it is a systemic problem, and topicals will keep losing to it no matter how many you try. ↗The older systemic options still have a place in that conversation, particularly where access to biologics is limited.

The honest limitation on all of this is not clinical, it is economic and administrative. The newer topicals and every biologic are expensive, subject to formulary rules, and often gated behind documented failure of cheaper options — which means the ladder in the guidelines and the ladder available to you may not be the same ladder. Knowing what the rungs do is still how you have that argument. The alternative is a fourth year on the same tube, hoping this time it is different.